文献速递类风湿关节炎

早期类风湿关节炎一线生物/靶向合成DMARDs与甲氨蝶呤的缓解结局荟萃分析

First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

结果显示b/tsDMARDs联合甲氨蝶呤在6、3、12个月均显著提高DAS28缓解率,单药治疗中仅托珠单抗和JAK抑制剂显著优于甲氨蝶呤。

要点

  • b/tsDMARDs联合甲氨蝶呤较甲氨蝶呤单药显著提高6个月DAS28缓解率(RR 1.62)。
  • 单药治疗中仅托珠单抗和JAK抑制剂较甲氨蝶呤显著提高缓解率。
  • 基线疾病活动度高和类风湿因子阳性比例高的研究中联合治疗获益更大。

核心结论

  • 早期RA初始b/tsDMARDs联合甲氨蝶呤较甲氨蝶呤单药获得更高的缓解率。
  • 单药治疗中JAK抑制剂和托珠单抗观察到更高缓解率。

研究设计与样本

  • 比较初始b/tsDMARDs(联合甲氨蝶呤或单药)与甲氨蝶呤,采用配对和网络荟萃分析。
  • 主要分析时间点为6个月,次要分析为3和12个月。

主要发现

  • 联合治疗组6个月DAS28缓解率显著高于甲氨蝶呤单药(RR 1.62;95%CI:1.39,1.89)。
  • 联合治疗组3个月(RR 1.95;95%CI:1.47,2.57)和12个月(RR 1.54;95%CI:1.39,1.71)DAS28缓解率亦显著提高。
  • 联合治疗组CDAI缓解和ACR50应答也观察到获益。
  • 网络荟萃分析中所有b/tsDMARD类别联合甲氨蝶呤的缓解率均高于甲氨蝶呤单药。
  • 单药治疗组6个月(RR 1.81;95%CI:1.42,2.31)、3个月(RR 1.92;95%CI:1.31,2.83)和12个月(RR 1.46;95%CI:1.25,1.71)DAS28缓解率显著高于甲氨蝶呤。

关键数值与推荐

  • 主要结局为DAS28缓解,次要结局包括ACR50应答和CDAI缓解。
  • 联合治疗在基线疾病活动度更高和类风湿因子阳性比例更高的研究中获益更大。

临床怎么用

  • 早期RA患者可考虑初始b/tsDMARDs联合甲氨蝶呤以提高缓解率。
  • 单药治疗时托珠单抗或JAK抑制剂可能优于甲氨蝶呤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate initial therapy with biologic and targeted synthetic DMARDs (b/tsDMARDs), compared with methotrexate, in patients with early RA. METHODS: We systematically reviewed and meta-analysed randomized-controlled trials comparing initial b/tsDMARDs, combined with methotrexate or as monotherapy, against methotrexate in methotrexate-naïve adults with early RA. Pairwise and network meta-analysis were performed to compare DAS28 remission attainment, with the primary analysis at 6 months and secondary analyses at 3 and 12 months. Secondary outcomes included ACR50 response and CDAI remission. RESULTS: Twenty-nine trials (13 387 participants) were included. Compared with methotrexate alone, initial b/tsDMARDs plus methotrexate significantly increased DAS28 remission at 6 months (risk ratio [RR] 1.62; 95% CI: 1.39, 1.89), 3 months (RR 1.95; 1.47, 2.57) and 12 months (RR 1.54; 1.39, 1.71), with benefits also observed for CDAI remission and ACR50 response. In network meta-analysis, all b/tsDMARD classes combined with methotrexate had higher remission rates than methotrexate alone. The benefits of b/tsDMARDs plus methotrexate were greater in studies with higher baseline disease activity and a greater proportion of rheumatoid factor-positive participants. As monotherapy, b/tsDMARDs increased DAS28 remission attainment compared with methotrexate at 6 months (RR 1.81; 1.42, 2.31), 3 months (RR 1.92; 1.31, 2.83) and 12 months (RR 1.46; 1.25, 1.71); however, at individual class level, significantly higher remission rates were observed only with tocilizumab and Janus kinase (JAK) inhibitor monotherapy. CONCLUSION: Initial therapy with b/tsDMARDs in combination with methotrexate is associated with higher remission rates than methotrexate alone in patients with early RA. As monotherapy, higher remission rates were observed for JAK inhibitors and tocilizumab.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Russell MD, Chan CJ, Sasitharan A, et al. First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes. Rheumatology (Oxford). 2026. PMID: 42755040. doi:10.1093/rheumatology/keag515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。